These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 34412695)

  • 1. HIV screening and retention in care in people who use drugs in Madrid, Spain: a prospective study.
    Ryan P; Valencia J; Cuevas G; Troya J; Torres-Macho J; Muñoz-Gómez MJ; Muñoz-Rivas N; Canorea I; Vázquez-Morón S; Resino S
    Infect Dis Poverty; 2021 Aug; 10(1):111. PubMed ID: 34412695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCV screening based on dried blood samples and linkage to care in people who use drugs: A prospective study.
    Ryan P; Valencia J; Cuevas G; Troya J; Ramon C; Rodríguez A; Torres-Macho J; Muñoz-Gómez MJ; Canorea I; Vázquez-Morón S; Resino S
    Int J Drug Policy; 2021 Jun; 92():103134. PubMed ID: 33517130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of active hepatitis C in a single visit and linkage to care among marginalized people using a mobile unit in Madrid, Spain.
    Ryan P; Valencia J; Cuevas G; Torres-Macho J; Troya J; Pueyo Á; José Muñoz-Gómez M; Muñoz-Rivas N; Vázquez-Morón S; Martinez I; Lazarus JV; Resino S
    Int J Drug Policy; 2021 Oct; 96():103424. PubMed ID: 34429222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in active hepatitis C infection among people who use drugs in Madrid, Spain, 2017 to 2023: a retrospective study.
    Ryan P; Valencia J; Cuevas G; Amigot-Sanchez R; Martínez I; Lazarus JV; Pérez-García F; Resino S
    Euro Surveill; 2024 Jul; 29(29):. PubMed ID: 39027941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Janssens F; Van den Bergh L; Van Lint P; Bruckers L; Nevens F; Robaeys G
    BMC Public Health; 2021 Aug; 21(1):1574. PubMed ID: 34416867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017).
    Scheibe A; Young K; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Puren A; Hausler H
    BMC Infect Dis; 2020 Sep; 20(1):655. PubMed ID: 32894072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain.
    Saludes V; Antuori A; Lazarus JV; Folch C; González-Gómez S; González N; Ibáñez N; Colom J; Matas L; Casabona J; Martró E
    Int J Drug Policy; 2020 Jun; 80():102734. PubMed ID: 32470849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of HIV, viral hepatitis B/C and tuberculosis and treatment outcomes among people who use drugs: Results from the implementation of the first drop-in-center in Mozambique.
    Semá Baltazar C; Kellogg TA; Boothe M; Loarec A; de Abreu E; Condula M; Fazito E; Raymond HF; Temmerman M; Luchters S
    Int J Drug Policy; 2021 Apr; 90():103095. PubMed ID: 33429163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HCV point-of-care screening programme and treatment options for people who use drugs in a metropolitan area of Southern Italy.
    Persico M; Masarone M; Aglitti A; Armenante C; Giordano A; Guardiola A; Raimondi G; Contaldi C; Nigro C; Marena G; De Luna A
    Liver Int; 2019 Oct; 39(10):1845-1851. PubMed ID: 31169953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining rapid diagnostic tests and dried blood spot assays for point-of-care testing of human immunodeficiency virus, hepatitis B and hepatitis C infections in Burkina Faso, West Africa.
    Kania D; Bekalé AM; Nagot N; Mondain AM; Ottomani L; Meda N; Traoré M; Ouédraogo JB; Ducos J; Van de Perre P; Tuaillon E
    Clin Microbiol Infect; 2013 Dec; 19(12):E533-41. PubMed ID: 23902574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky.
    Duong M; Delcher C; Freeman PR; Young AM; Cooper HLF
    J Rural Health; 2022 Jan; 38(1):93-99. PubMed ID: 33666274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eliminating hepatitis C on the Balearic Islands, Spain: a protocol for an intervention study to test and link people who use drugs to treatment and care.
    Lazarus JV; Herranz A; Picchio CA; Villota-Rivas M; Rodríguez A; Alonso JM; Moratinos A; Perrotta A; Tegeo E; Bibiloni F; Buti M; Vilella À
    BMJ Open; 2021 Oct; 11(10):e053394. PubMed ID: 34675021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of hepatitis C in decentralised versus centralised drug substitution programmes and minimally invasive point-of-care tests to close gaps in the HCV cascade.
    Bregenzer A; Conen A; Knuchel J; Friedl A; Eigenmann F; Näf M; Ackle P; Roth M; Fux CA
    Swiss Med Wkly; 2017; 147():w14544. PubMed ID: 29185250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hepatitis C care cascade among people who inject drugs accessing harm reduction services in Catalonia: Major gaps for migrants.
    Folch C; Saludes V; Reyes-Ureña J; Antuori A; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2021 Apr; 90():103057. PubMed ID: 33310634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and treatment of viral hepatitis C in persons who use drugs: a prospective, multicenter outreach study in Flanders, Belgium.
    Busschots D; Kremer C; Bielen R; Koc ÖM; Heyens L; Dercon E; Verrando R; Windelinckx T; Maertens G; Bourgeois S; Hens N; Matheï C; Robaeys G
    Harm Reduct J; 2021 May; 18(1):54. PubMed ID: 34001145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV and hepatitis C treatment uptake among people who use drugs participating in the Amsterdam Cohort Studies, 1985-2015.
    van Santen DK; van der Helm JJ; Lindenburg K; Schim van der Loeff M; Prins M
    Int J Drug Policy; 2017 Sep; 47():95-101. PubMed ID: 28606392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utility of a one-step screening and diagnosis strategy for viremic HCV infection among people who inject drugs in Catalonia.
    Saludes V; Antuori A; Folch C; González N; Ibáñez N; Majó X; Colom J; Matas L; Casabona J; Martró E;
    Int J Drug Policy; 2019 Dec; 74():236-245. PubMed ID: 31706159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
    Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
    World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing Read Time of Point-of-Care Test Does Not Affect Detection of Hepatitis C Virus and Reduces Need for Reflex RNA.
    Smookler D; Vanderhoff A; Biondi MJ; Valencia J; Ryan P; Karkada J; Hong R; Sattar I; Mandel E; Gjevori M; Casey J; Fletcher D; Shah H; Hansen BE; Capraru C; Janssen HLA; Lazarus JV; Feld JJ
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1451-1458.e4. PubMed ID: 32763480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs.
    Chevaliez S; Wlassow M; Volant J; Roudot-Thoraval F; Bachelard A; Poiteau L; Trabut JB; Hézode C; Bourdel A; Dominguez S
    Open Forum Infect Dis; 2020 Jun; 7(6):ofaa196. PubMed ID: 32617372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.